| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
1,430,000,000 |
| Market
Cap: |
106.61(B) |
| Last
Volume: |
5,636,901 |
Avg
Vol: |
8,454,629 |
| 52
Week Range: |
$48.64 - $74.1 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 297 |
| Guru Rank Value : 4.1 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Boston Scientific develops, manufactures and markets medical devices. Co.'s Medical Surgical segment consist of: Endoscopy, which develops and manufactures devices to diagnose and treat a range of gastrointestinal and pulmonary conditions; and Urology and Pelvic Health, which develops and manufactures devices to treat various urological and pelvic conditions. Co.'s Rhythm and Neuro segment includes: Cardiac Rhythm Management, which develops and manufactures implantable devices to treat cardiac abnormalities; and Electrophysiology, which develops and manufactures medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
131,028 |
305,705 |
848,086 |
1,903,760 |
| Total Sell Value |
$9,081,880 |
$19,161,337 |
$47,794,933 |
$94,196,882 |
| Total People Sold |
8 |
9 |
11 |
13 |
| Total Sell Transactions |
13 |
23 |
39 |
74 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Burns Brian R |
EVP - Global Quality & Reg Aff |
• – – |
2011-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,993 |
51,375 |
|
- |
|
| Mario Ernest |
Director |
– • – |
2011-02-07 |
4 |
B |
$6.94 |
$346,990 |
D/D |
50,000 |
131,004 |
2.39 |
- |
|
| Dawkins Keith D |
Sr. VP, Chief Medical Officer |
• – – |
2011-01-07 |
4 |
D |
$7.28 |
$28,195 |
D/D |
(3,873) |
43,846 |
|
- |
|
| Dawkins Keith D |
Sr. VP, Chief Medical Officer |
• – – |
2011-01-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,771 |
47,719 |
|
- |
|
| Johnson Kristina M |
Director |
– • – |
2011-01-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,124 |
|
- |
|
| Fitzgerald Joseph Michael |
SVP & President, Endovascular |
• – – |
2011-01-03 |
4 |
D |
$7.60 |
$2,272 |
D/D |
(299) |
43,674 |
|
- |
|
| Fitzgerald Joseph Michael |
SVP & President, Endovascular |
• – – |
2011-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
767 |
43,973 |
|
- |
|
| Onuscheck John Michael |
SVP & Pres-Neuromodulation |
• – – |
2011-01-03 |
4 |
D |
$7.60 |
$1,923 |
D/D |
(253) |
30,761 |
|
- |
|
| Onuscheck John Michael |
SVP & Pres-Neuromodulation |
• – – |
2011-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
588 |
31,014 |
|
- |
|
| Elliott John Raymond |
President and CEO |
• • – |
2010-12-31 |
4 |
D |
$7.57 |
$1,580,268 |
D/D |
(208,754) |
409,510 |
|
- |
|
| Elliott John Raymond |
President and CEO |
• • – |
2010-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
500,000 |
618,264 |
|
- |
|
| Lance Jean Fitterer |
SVP & Chief Compliance Officer |
• – – |
2010-11-15 |
4 |
AS |
$6.74 |
$19,971 |
D/D |
(2,963) |
53,835 |
|
- |
|
| Lance Jean Fitterer |
SVP & Chief Compliance Officer |
• – – |
2010-11-15 |
4 |
OE |
$6.13 |
$18,148 |
D/D |
2,963 |
56,798 |
|
- |
|
| Pedersen John B. |
Pres, Uro & Womens Health |
• – – |
2010-11-12 |
4 |
S |
$6.77 |
$23,716 |
D/D |
(3,502) |
0 |
|
- |
|
| Mario Ernest |
Director |
– • – |
2010-11-04 |
4 |
B |
$6.44 |
$64,393 |
D/D |
10,000 |
81,004 |
2.39 |
- |
|
| Nicholas Peter M |
Director |
– • – |
2010-11-03 |
4 |
AS |
$6.43 |
$160,678 |
I/I |
(25,000) |
3,531,021 |
|
- |
|
| Nicholas Peter M |
Director |
– • – |
2010-11-02 |
4 |
AS |
$6.40 |
$159,963 |
I/I |
(25,000) |
3,556,021 |
|
- |
|
| Nicholas Peter M |
Director |
– • – |
2010-11-01 |
4 |
AS |
$6.36 |
$159,083 |
I/I |
(25,000) |
3,581,021 |
|
- |
|
| Pucel Kenneth |
EVP, Global Operations |
• – – |
2010-11-01 |
4 |
D |
$6.32 |
$13,436 |
D/D |
(2,126) |
71,374 |
|
- |
|
| Pucel Kenneth |
EVP, Global Operations |
• – – |
2010-11-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,500 |
73,500 |
|
- |
|
| Kucheman William |
EVP, Cardiology |
• – – |
2010-11-01 |
4 |
D |
$6.32 |
$13,044 |
D/D |
(2,064) |
54,565 |
|
- |
|
| Kucheman William |
EVP, Cardiology |
• – – |
2010-11-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,500 |
56,629 |
|
- |
|
| Onuscheck John Michael |
SVP & Pres-Neuromodulation |
• – – |
2010-11-01 |
4 |
D |
$6.32 |
$5,309 |
D/D |
(840) |
30,426 |
|
- |
|
| Onuscheck John Michael |
SVP & Pres-Neuromodulation |
• – – |
2010-11-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,290 |
31,266 |
|
- |
|
| Nicholas Peter M |
Director |
– • – |
2010-10-29 |
4 |
AS |
$6.34 |
$158,560 |
I/I |
(25,000) |
3,606,021 |
|
- |
|
1824 Records found
|
|
Page 29 of 73 |
|
|
0.10 (0.13%) 
